Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 12/06 02:22:13 pm
145.555 USD   -9.30%
12/03Novavax Statement on Omicron Variant Response
AQ
12/02INSIDER SELL : Novavax
MT
12/02Novavax Begins Development of Omicron-Specific Vaccine, Manufacturing Expected in January -- Stock Plunges
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novavax : B. Riley Raises Novavax's PT to $305 from $286, Notes Potential to Supply Higher-than-Projected Vaccine Doses by Year End; Keeps Buy Rating

08/09/2021 | 09:12am EST


ę MT Newswires 2021
All news about NOVAVAX, INC.
12/03Novavax Statement on Omicron Variant Response
AQ
12/02INSIDER SELL : Novavax
MT
12/02Novavax Begins Development of Omicron-Specific Vaccine, Manufacturing Expected in Janua..
MT
12/02What COVID-19 vaccine and drug makers have to say about Omicron
RE
12/02Novavax To Start Development of Vaccine Against New COVID-19 Variant
MT
12/02Novavax Initiates Development of Omicron-Specific Vaccine
MT
12/02NOVAVAX : StatementCOVID-19
PU
12/02MarketScreener's World Press Review - December 2, 2021
12/02Japan's Fujifilm Plans $532 Million Investment in UK to Expand COVID-19 Vaccine Making ..
MT
12/01UK agrees deals for 114 million more Moderna and Pfizer COVID-19 doses
RE
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2021 1 396 M - -
Net income 2021 -905 M - -
Net cash 2021 756 M - -
P/E ratio 2021 -13,2x
Yield 2021 -
Capitalization 12 134 M 12 134 M -
EV / Sales 2021 8,15x
EV / Sales 2022 2,11x
Nbr of Employees 792
Free-Float 98,5%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 160,48 $
Average target price 260,60 $
Spread / Average Target 62,4%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.72.76%12 134
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-42.48%24 298